Testing linvoseltamab with lenalidomide for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were recently diagnosed with multiple myeloma and have completed your initial treatment, which included at least two types of drugs (immunomodulatory drug, proteosome inhibitor, or anti-CD38 antibody).
- You are currently on lenalidomide maintenance therapy and have been on it for no more than 12 months.
- Your disease has not fully disappeared (MRD positive) or has come back after a complete response, but you don't meet the criteria for a full relapse.
- You are in generally good health, with adequate blood counts, liver and kidney function, and are able to care for yourself (ECOG performance status 0-3).
- You have not had any other treatments for multiple myeloma besides your initial therapy and lenalidomide maintenance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy drug combination for people newly diagnosed with multiple myeloma who have had some response to initial treatment but still have signs of disease. The goal is to see if this approach can help eliminate remaining cancer cells and potentially improve outcomes.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests an experimental BCMA bispecific antibody called linvoseltamab for people with multiple myeloma that has returned after BCMA CAR T-cell therapy. The goal is to see if this new approach can still fight the cancer effectively.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.